 "Biocon's facility. Photo: Company's website")
Bringing access to another biosimilar, biopharmaceutical-major Biocon has launched Trastuzumab biosimilar Ogivri in the US market. Ogivri, a biosimilar to Herceptin, has been co-developed by Biocon Biologics and Mylan and will be available in 150 mg and 420 mg strengths.
Ogivri will be launched at a competitive discount for customers to help ensure access and increase treatment options for patients, said the Bengaluru-based company.
“The US launch of Ogivri marks a significant milestone in our biosimilars journey. It is an important endorsement of our science, development and manufacturing capabilities in the area of monoclonal antibodies,” said Christiane Hamacher, CEO, Biocon Biologics.
Biocon Biologics,
